- Home
- AG vs SDGR Comparison
AG vs SDGR Comparison
Compare AG & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AG
- SDGR
- Stock Information
- Founded
- AG 1979
- SDGR 1990
- Country
- AG Canada
- SDGR United States
- Employees
- AG N/A
- SDGR N/A
- Industry
- AG Precious Metals
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- AG Basic Materials
- SDGR Health Care
- Exchange
- AG Nasdaq
- SDGR Nasdaq
- Market Cap
- AG 1.9B
- SDGR 1.6B
- IPO Year
- AG N/A
- SDGR 2020
- Fundamental
- Price
- AG $5.73
- SDGR $21.33
- Analyst Decision
- AG Buy
- SDGR Buy
- Analyst Count
- AG 2
- SDGR 10
- Target Price
- AG $8.50
- SDGR $32.90
- AVG Volume (30 Days)
- AG 12.8M
- SDGR 580.3K
- Earning Date
- AG 02-20-2025
- SDGR 02-26-2025
- Dividend Yield
- AG 0.31%
- SDGR N/A
- EPS Growth
- AG N/A
- SDGR N/A
- EPS
- AG N/A
- SDGR N/A
- Revenue
- AG $525,212,999.00
- SDGR $193,348,000.00
- Revenue This Year
- AG N/A
- SDGR N/A
- Revenue Next Year
- AG $45.50
- SDGR $26.50
- P/E Ratio
- AG N/A
- SDGR N/A
- Revenue Growth
- AG N/A
- SDGR N/A
- 52 Week Low
- AG $4.17
- SDGR $16.67
- 52 Week High
- AG $8.44
- SDGR $33.63
- Technical
- Relative Strength Index (RSI)
- AG 47.53
- SDGR 57.61
- Support Level
- AG $5.40
- SDGR $18.63
- Resistance Level
- AG $6.07
- SDGR $20.20
- Average True Range (ATR)
- AG 0.31
- SDGR 1.05
- MACD
- AG 0.03
- SDGR 0.02
- Stochastic Oscillator
- AG 46.30
- SDGR 74.88
About AG First Majestic Silver Corp. (Canada)
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines, in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine and the La Encantada Silver Mine.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.